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South Africa has an estimated 5.7 million individuals infected with 
HIV, 350 000 people died from AIDS-related complications in 2007,1,2 
and about one-third of all pregnant women are HIV infected.3,4 The 
growth of the HIV epidemic has led to rapid expansion of HIV care 
and treatment.2 
Many non-governmental organisations (NGOs) operate mentoring 
and support programmes for HIV-infected people in resource-
limited countries.5,6 In South Africa, faith-based organisations play 
a significant and expanding role in providing HIV care and access 
to antiretroviral therapy (ART).7,8 One of the largest of these 
programmes is jointly run by the Southern African Catholic Bishops’ 
Conference (SACBC) and the Catholic Relief Services (CRS) and 
is funded by the US President’s Emergency Plan for AIDS Relief 
(PEPFAR).9 The ART treatment programme operated by the SACBC 
and the CRS is spread widely across South Africa and is involved in 
locally based HIV responses in many South African communities.10 
Evaluating the outcomes of patients initiating ART is critical for 
ART treatment programmes. However, outcomes are generally based 
only on patients who remain in care.11 High rates of loss to follow-
up (LTFU) diminish treatment options and substantially limit the 
effectiveness of ART strategies.12,13 Furthermore, evidence suggests 
heterogeneity in rates of LTFU for men and women.14 Pregnancy may 
also contribute to higher rates of suboptimal retention in care.15 There 
is therefore an urgent need for a better understanding of LTFU in 
patients who initiate ART. We aimed to identify the impact of gender, 
pregnancy status and CD4 count on LTFU 6 months after ART 
initiation in one of the largest SACBC/CRS treatment programmes 
in South Africa.
Methods
Setting
This study was conducted in Tapologo, one of the SACBC/CRS HIV 
treatment clinics that work with mine worker communities in the 
greater Rustenburg area of the North West province of South Africa.16 
Through a network of caregivers, Tapologo provides home-based care, Corresponding author: E Losina (elosina@partners.org)
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Background. Faith-based organisations have expanded antiretroviral 
therapy (ART) in community clinics across South Africa. Loss to 
follow-up (LTFU), however, limits the potential individual and 
population treatment benefits and optimal care. 
Objective. To identify patient characteristics associated with 
LTFU 6 months after starting ART in a large community clinic.
Methods. Patients initiating ART between April 2004 and 
October 2006 in one South African Catholic Bishops’ Conference 
HIV treatment clinic who had at least one follow-up visit were 
included and routinely monitored every 6 months after ART 
initiation. Standardised instruments were used to collect data. Rates 
of LTFU over time were estimated by the Kaplan-Meier method. 
The Cox proportional hazard regression examined the impact of 
age, baseline CD4 count, baseline HIV RNA, gender and pregnancy 
status on LTFU. 
Results. Data from 925 patients (age >14 years, median age 36 
years, 70% female, of whom 16% were pregnant) were included: 51 
(6%) were lost to follow-up 6 months after ART initiation. Younger 
age (≤30 years) (hazard ratio (HR) 2.14, 95% confidence interval 
(CI) 1.05 - 4.38) and pregnancy for women (HR 3.75, 95% CI 1.53 
- 9.16) were significantly associated with higher LTFU rates. When 
stratified by baseline CD4 count, gender and pregnancy status, 
pregnant women with lower baseline CD4 counts (≤200 cells/
µl) had 6.06 times the hazard (95% CI 2.20 - 16.71) of LTFU at 6 
months compared with men. 
Conclusions. HIV-infected pregnant women initiating ART were 
significantly more likely to be lost to follow-up in a community 
clinic in South Africa. Urgent interventions to successfully retain 
pregnant women in care are needed. 
S Afr Med J 2011;101:253-257.
254
ORIGINAL ARTICLES
April 2011, Vol. 101, No. 4  SAMJ
local clinical consultation and support services to migrant workers 
and men and women in informal settlements around the mines.17 
The clinic population comprises urban adults (age >14 years) in the 
mining community. They receive ART from home-based caregivers 
who are supported financially by the platinum mines, the SACBC 
and other partners. The clinic employs doctors, nurses, counsellors 
and adherence monitors.17 Treatment protocols closely follow South 
African National Department of Health (DOH) guidelines.18,19 
Adherence education is given before and during ART. Tapologo 
clinic services offered for pregnant women include counselling and 
emotional support, HIV/AIDS education and awareness, positive 
living, and food security and nutrition. Clinical services include HIV 
testing, treatment of tuberculosis and other life-threatening diseases, 
general medical care, and treatment of sexually transmitted and 
opportunistic infections.
Study sample
The cohort included HIV-infected patients who either developed 
AIDS or had a CD4 count that met criteria for ART initiation based 
on DOH guidelines at that time (CD4 ≤200/µl).19 Patients initiating 
ART between January 2004 and October 2006 and eligible for at least 
one follow-up visit were included. After ART initiation patients were 
followed up every 6 months, with CD4 counts and HIV RNA tests 
done at each clinic visit.
Data elements
Standardised data reporting forms were used to collect data. 
Demographic characteristics at baseline included date of birth 
(or age) and sex. Clinical characteristics included WHO stage at 
enrollment, height, weight, pregnancy status for women, functional 
status and ART history. CD4 count and HIV RNA were measured 
at the initiation of ART and at each clinic visit. All records were 
maintained by the local site.
Definition of outcomes 
The outcome for the study was defined as the proportion of LTFU in 
patients initiating ART. Two definitions for LTFU were considered: 
the clinic-based definition, used in the main analysis, was determined 
by the Tapologo-based provider as failure to return for a scheduled 
consultation or medication pick-up within 6 months after ART 
initiation;13 and the data-based definition was a lack of recorded 
information in the database on a patient returning for a 6-month 
visit. LTFU was determined according to the data-based definition 
if no information was recorded for a patient with respect to the date 
of the 6-month follow-up visit and there was no laboratory testing 
(CD4 or HIV RNA tests) within 6 months of ART initiation. The 
data-based definition was used in sensitivity analyses.
Statistical analysis
Data available on 30 April 2007 on all patients with at least 6 months 
of follow-up time were analysed. At 6 months after ART initiation, 
patients who had unknown drop-out status, had ART discontinued 
by their physician, had voluntarily discontinued treatment, had 
been transferred out of the programme or had died were censored. 
Study time for each patient was therefore calculated from the date 
of ART initiation until the date of drop-out, if known, or the date 6 
months after ART initiation, if the date of drop-out was unknown. 
For patients lost to follow-up at 6 months after ART initiation, study 
time was calculated from the date of ART initiation until the date of 
LTFU. Kaplan-Meier estimates were used to analyse the cumulative 
probability of LTFU. The log-rank test examined differences in LTFU 
rates within patient subgroups.
Demographic and clinical variables were grouped as categorical: 
age (≤30, 31 - 40, >40 years), gender and pregnancy status (pregnant 
women, non-pregnant women, men), baseline CD4 count (≤200/µl, 
>200/µl), and baseline HIV RNA (≤100 000 copies/ml, >100 000 
copies/ml). To determine the effect of baseline CD4, gender and 
pregnancy status on LTFU, we stratified pregnancy status by baseline 
CD4 count for women (>200/µl and ≤200/µl), but not for men as they 
had no LTFU events with baseline CD4 >200/µl. Such stratification 
resulted in a variable with five categories: pregnant women with CD4 
≤200/µl, pregnant women with CD4 >200/µl, non-pregnant women 
with CD4 ≤200/µl, non-pregnant women with CD4 >200/µl, and 
men. For individual and stratified variables, hazard ratios (HRs) 
with corresponding 95% confidence intervals (CIs) for LTFU were 
analysed through Cox proportional hazard regression. Two-sided 
p-values <0.05 were considered statistically significant. Analyses were 
performed using SAS software (version 9.1 or higher, SAS Institute 
Inc., Cary, NC, USA).
Results
Cohort characteristics 
Among adult patients (age >14 years) accessing SACBC/CRS clinics 
in Tapologo, 925 met the criteria for analysis. Their median age was 
36 years (interquartile range (IQR) 29 - 44), and 645 (70%) were 
female, of whom 16% were pregnant. At ART initiation, the median 
CD4 count was 111/µl (IQR 41 - 214/µl) and the median HIV RNA 
4.9 log10 copies/ml (IQR 4.4 - 5.4). On initiating ART, approximately 
45% of patients had a baseline HIV RNA >100 000 copies/ml; 72% of 
patients and one-third of pregnant women had a baseline CD4 count 
≤200/µl (Table I).
Reasons for discontinuing ART 
Of the patients 322 (35%) discontinued ART within 6 months 
of ART initiation. Among them 37 (11%) were discontinued by 
physician recommendation, 21 (7%) transferred out of the Tapologo 
programme, 213 (66%) died, and 51 (16%) were lost to follow-up (the 
clinic-based definition). Patients with unknown drop-out status were 
considered as remaining in care and were subsequently censored 6 
months after ART initiation. 
Association between patient characteristics 
and LTFU 6 months after ART initiation
Kaplan-Meier analysis indicated that during the study the cumulative 
probability of LTFU 6 months after ART initiation was 6% (95% CI 
4 - 7%) for the cohort. Log-rank tests showed that the cumulative 
probability of LTFU was significantly different across the sex and 
pregnancy subgroups (p=0.01). The cumulative probability of LTFU 
6 months after ART initiation was 12% (95% CI 5 - 18%) for pregnant 
women, 6% (95% CI 4 - 8%) for non-pregnant women, and 3% (95% 
CI 1 - 5%) for men (Table II).
Cox proportional hazard regression analyses quantified the effect 
of all characteristics on LTFU (Table II). Younger age (≤30 years) 
(HR 2.14, 95% CI 1.05 - 4.38), and pregnancy for women (HR 3.75, 
95% CI 1.53 - 9.16) were significantly related to higher LTFU rates 
at 6 months from ART initiation. However, in terms of the overall 
effect, gender and pregnancy status was the only factor showing a 
statistically significant association with LTFU (p=0.01). 
Although we did not find an overall association between baseline 
CD4 and LTFU at 6 months, there was a significant impact on LTFU 
related to pregnancy in the lower CD4 stratum. If baseline CD4 was 
≤200/µl, pregnant women had 3.62 times of hazard of LTFU compared 
with non-pregnant women (95% CI 1.52 - 8.62). To examine this joint 
effect, gender and pregnancy status was further stratified by baseline 
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Table I. Baseline characteristics of HIV-infected patients initiating ART in the Tapologo community clinic in South Africa
Characteristics
Men  
(N=280)
Non-pregnant women 
(N=541)
Pregnant women  
(N=104)
Total  
(N=925)
Age (yrs) (N (%))
   ≤30 39 (14) 157 (29) 73 (70) 269 (29)
    31 - 40 93 (33) 209 (39) 29 (28) 331 (36)
   >40 148 (53) 175 (32) 2 (2) 325 (35)
Baseline HIV RNA 
(copies/ml) (N (%))
    ≤100 000 136 (49) 284 (53) 87 (84) 507 (55)
    >100 000 143 (51) 252 (47) 17 (16) 412 (45)
Baseline CD4 count  
(cells/μl) (N (%))
    ≤200 220 (79) 411 (76) 35 (34) 666 (72)
    >200 58 (21) 125 (23) 69 (66) 252 (27)
ART = antiretroviral therapy.
CD4, and proportional hazard regression analyses were conducted. 
Pregnant women with baseline CD4 ≤200/µl had the highest risk of 
LTFU 6 months after ART initiation (HR 6.06, 95% CI 2.20 - 16.71), 
followed by non-pregnant women with baseline CD4 >200/µl (HR 
2.91, 95% CI 1.19 - 7.11) and pregnant women with baseline CD4 
>200/µl (HR 2.44, 95% CI 0.80 - 7.46) (Table III, Fig. 1).
Sensitivity analysis: the impact of the 
definition of LTFU
To detect the impact of alternative definitions of LTFU, we conducted 
sensitivity analyses using the data-based definition of LTFU; 95 
patients (10%) were lost to follow-up 6 months after initiating 
ART. Proportional hazard regression analysis showed that pregnant 
Table II. Association between demographics, clinical characteristics and rates of loss to follow-up at 6 months (clinic-based defini-
tion)
Total LTFU HR
(N (%)) (N (%))* (95% CI) p-value
Total 925 (100) 51 - -
Age (yrs) 0.11
   ≤30 269 (29) 20 (7) 2.14 (1.05 - 4.38)
   31 - 40 331 (36) 19 (6) 1.53 (0.74 - 3.16)
   >40 325 (35) 12 (4)   1.00
Baseline HIV RNA 
(copies/ml)
0.17
   ≤100 000 507 (55) 35 (7) 1.51 (0.83 - 2.72)
   >100 000 416 (45) 16 (4)   1.00
Baseline CD4 count  
(cells/µl)
0.73
   ≤200 666 (72) 34 (5) 0.90 (0.50 - 1.62)
   >200 252 (27) 17 (7)   1.00
Gender and pregnancy 
status
0.01
   Pregnant women 104 (11) 12 (12) 3.75 (1.53 - 9.16)
   Non-pregnant women 541 (58) 31 (6) 1.98 (0.91 - 4.30)
   Men 280 (30) 8 (3)   1.00
*% refers to the proportion of those LTFU among patients within each group.
Clinic-based definition = failure to return for a scheduled consultation or medication pick-up within 6 months after ART initiation; LTFU = loss to follow-up; HR = hazard ratio; CI = confi-
dence interval.
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women with baseline CD4 ≤200/µl had the highest risk of LTFU 6 
months after ART initiation (HR 2.67, 95% CI 1.12 - 6.35), followed 
by pregnant women with baseline CD4 >200/µl (HR 2.40, 95% CI 
1.14 - 5.05) and non-pregnant women with baseline CD4 >200/µl 
(HR 2.29, 95% CI 1.24 - 4.24) (Table III). The overall joint effects of 
baseline CD4, gender and pregnancy status on LTFU were similar for 
clinic- and data-based definitions of LTFU.
Discussion
In the community-based cohort of 925 adults eligible for ART, we 
analysed patient characteristics associated with LTFU 6 months after 
ART initiation. Gender and pregnancy status was significantly related 
to LTFU, and pregnant women had the highest risk of LTFU.
 In ART programmes in resource-limited settings, LTFU is a major 
problem for optimal care of HIV-infected individuals.13,15,20 Studies 
describing associations with LTFU in ART treatment programmes 
in South Africa have used chart reviews to investigate patient 
characteristics predicting LTFU in large ART treatment programmes 
in public hospitals. Causes of LTFU included financial difficulty, lack 
of patient knowledge that ART needs to be lifelong, hospitalisation or 
illness, medication toxicity, CD4 count increase, and death.20,21 Little 
work has focused on the relationship between LTFU and gender and 
pregnancy.15 With an HIV prevalence among pregnant women in 
South Africa of 20 - 30%, further understanding of LTFU among 
pregnant women on ART could help improve their retention in care 
and may also decrease risk of mother-to-child HIV transmission.8,15,22 
We identified characteristics including gender and pregnancy status 
associated with LTFU in patients who began ART in the Tapologo 
programme, one of SACBC/CRS HIV care and treatment clinics in 
North West province, South Africa. 
Although there was insufficient statistical evidence to support 
an association between baseline clinical characteristics (HIV RNA 
or CD4 count) and LTFU 6 months after ART initiation, the 
distributions of these clinical characteristics in pregnant women 
differed from non-pregnant women and men. The stratified analysis 
in baseline CD4 ≤200/µl also showed that pregnant women were 
more likely to be lost to care than non-pregnant women. This 
evidence indicates the possible joint effects of clinical characteristics, 
gender and pregnancy status. To detect the joint effects of baseline 
CD4, gender and pregnancy status, we stratified pregnancy status by 
baseline CD4 count for women because there were no LTFU events 
for men with high baseline CD4 counts based on the preliminary 
results. A Cox proportional hazard model quantified the joint 
effects on LTFU. Sensitivity analyses using a second standardised 
(data-based) definition of LTFU examined the impact of different 
definitions on LTFU. Although HIV-infected non-pregnant women 
who initiated ART and had higher CD4 counts were significantly 
more likely to be lost to care, pregnant women initiating ART at 
all stages of HIV disease were at substantial risk of LTFU, with its 
attendant risk of developing an AIDS-defining illness or of death. 
Our data suggested that the relationship between CD4 count and 
LTFU among women was modified by pregnancy status. Women with 
high CD4 counts were at similar risk of LTFU regardless of pregnancy 
Fig. 1. Cumulative probability of loss to follow-up 6 months from ART initia-
tion, stratified by baseline CD4, gender and pregnancy status. Differences 
among all groups are highly significant by Kaplan-Meier analysis.
Table III. Cox proportional hazard regression of LTFU at 6 months on baseline CD4 and sex and pregnancy status for both the 
clinic-based and the data-based definitions
Clinic-based definition Data-based definition
(p=0.01) (p=0.02)
LTFU HR LTFU HR
(N (%))* (95% CI) (N (%))* (95% CI)
Total 51 - 95 -
Baseline CD4 (cells/µl), gender 
and pregnancy status
   Pregnant women, CD4 ≤200 7 (20) 6.06 (2.20 - 16.71) 7 (20) 2.67 (1.12 - 6.35)
   Pregnant women, CD4 >200 5 (7) 2.44 (0.80 - 7.46) 11 (16) 2.40 (1.14 - 5.05)
    Non-pregnant women, CD4 
≤200
19 (5) 1.66 (0.73 - 3.80) 36 (9) 1.37 (0.79 - 2.39)
    Non-pregnant women, CD4 
>200
12 (10) 2.91 (1.19 - 7.11) 22 (18) 2.29 (1.24 - 4.24)
   Men 8 (3)    1.00 19 (7)    1.00
Clinic-based definition = failure to return for a scheduled consultation or medication pick-up within 6 months after ART initiation; data-based definition = missing any visit information for at 
least 6 months; LTFU = loss to follow-up; HR = hazard ratio; CI = confidence interval. 
*% refers to the proportion of those LTFU among patients within each group.
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status. In contrast, pregnant women with low CD4 counts were at 
increased risk for LTFU compared with non-pregnant women. This 
discrepancy may be due to the increased burden of health and social 
conditions, including pregnancy, that HIV-infected women face. The 
stigma associated with HIV disease may explain the higher rates of 
LTFU among the women with higher CD4.
This study had several limitations. First, the reasons why pregnant 
women stopped treatment were not available. In mining communities 
in South Africa, many women live in shacks with no stable income 
and no stable partner to support them. Many have no access to potable 
water, decent sanitation or adequate nutrition. Although this ART 
programme was a local clinic that provided community-based care at 
no cost, pregnancy is a financial burden for women and their families. 
The higher proportion of LTFU among pregnant women may be due 
to lack of financial support and increased prenatal care costs. Since 
many women around the mines are from other parts of South Africa 
or other countries, physical relocation may be a risk factor for failure 
to return for further visits. Another explanation of LTFU among 
pregnant women may be that some of them may transfer out of the 
SACBC/CRS ART treatment programmes to maternal care facilities 
or to hospitals without informing local clinic staff. To ensure that 
pregnant women receive timely treatment and care for HIV during 
pregnancy and the postpartum period, improved linkage with other 
ARV centres and maternal services via data sharing to systematically 
monitor patients is critical. Patient records were maintained by the 
local site; however, there were no data for about 10% of the Tapologo 
patients. To perform this analysis, we conservatively assumed that 
patients with missing current treatment status were in care, which 
probably underestimated the rates of LTFU.11 Since this study was 
limited to one clinic in the programmes of the SACBC/CRS it may 
not be representative of the population of persons with HIV initiating 
ART in South Africa.
This was the first systematic study of LTFU in the programmes 
of the SACBC and CRS in South Africa. Pregnant women with HIV 
disease initiating ART were at the greatest risk of being lost to follow-
up. To ensure the best outcomes for HIV-infected women, and to 
prevent HIV transmission from mother to child, interventions to 
successfully retain pregnant women in care are urgently needed. 
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